Highlights of the Annual Meeting of the European Association of Nuclear Medicine: Brussels 1995: The art of imaging the body

European Journal of Nuclear Medicine

Volumn 23, Issue 1, 1996, Pages 75-90

  Corstens, Frans H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE;

BELGIUM; BRAIN TUMOR; BREAST CANCER; CARDIOVASCULAR DISEASE; INFECTION; INFLAMMATION; LUNG CARCINOMA; LUNG DISEASE; MELANOMA; NUCLEAR MEDICINE; ONCOLOGY; PARATHYROID DISEASE; REVIEW; SYMPOSIUM; THYROID DISEASE;

EUROPE; HUMANS; MEDICAL ONCOLOGY; NUCLEAR MEDICINE; RADIONUCLIDE IMAGING; RADIOTHERAPY; SOCIETIES, MEDICAL;

EID: 1542574238     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01736994     Document Type: Review

References (75)

1. Britton K. Highlights of the Annual Meeting of the European Association of Nuclear Medicine, Lausanne 1993. Eur J Nucl Med 1994; 21: 159-169.
2. 99mTc-MIBI (M) in breast cancer (BC): correlation with node (n) status, angiogenesis (A) and Ki-67 (K) staining [abstract]. Eur J Nucl Med 1995; 22: 726.
3. Palmedo H, Schomburg A, Grünwald F, Bender H, Mallmann P. Biersack HJ [abstract]. Mammoscintigraphy with Tc-99m MIBI in patients with suspicious breast nodules: a comparison of planar and SPECT imaging techniques [abstract]. Eur J Nucl Med 1995; 22: 725.
4. Avril N, Jänicke F, Dose J, Ziegler S, Bense S, Zincke M, Römer W, Weber W, Herz M, Schwaiger M. Evaluation of axillary lymph node involvement in breast cancer patients using F-18 FDG PET [abstract]. Eur J Nucl Med 1995; 22: 733.
5. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Schomäcker K, Theissen P, Schicha H. Qualitative [F-18]FDG-PET in breast tumors [abstract]. Eur J Nucl Med 1995; 22: 734.
6. Lietzenmayer R, Feine U, Hirnle P, Schmidt D, Müller-Schimpfle M, Kaiser W, Claussen CD, Müller-Schauenburg W. Whole body (WB) 18-FDG PET in primary and recurrent breast cancer: comparison with other imaging modalities and histology in 37 patients [abstract]. Eur J Nucl Med 1995; 22: 734.
7. Adalet I, Demirkol O, Müslümanoglu M, Koçak M, Bozfakioglu Y, Cantez S. Tc-99m tetrofosmin scintigraphy in the evaluation of palpable breast masses: preliminary results [abstract]. Eur J Nucl Med 1995; 22: 742.
8. Tiling R, Sommer H, Pechmann M, Kress K, Meyer G, Pfluger T, Tatsch K, Hahn K. Detection of carcinomas in mammographic dense breasts and mastopathies: GD-enhanced MRI versus semiquantitative Tc-99m sestamibi [abstract]. Eur J Nucl Med 1995; 22: 726.
9. Rijks LJM, de Bruin K, Bakker PJM, Veenhof CHN, Janssen AGM, van Royen EA. First results with the estrogen receptor radioligand Z-|I-123]mive in metastatic breast cancer patients [abstract]. Eur J Nucl Med 1995; 22: 743.
10. 123I-diethylstilbestrol diphosphate (DSEP) - biokinetics of a potential tracer for estrogen receptor-imaging (abstract). Eur J Nucl Med 1995; 22: 743.
11. Hoefnagel CA, Valdés Olmos RA, Rankin EM, Israëls SP. Melanoma detection using indium-111 pentetreotide [abstract]. Eur J Nucl Med 1995; 22: 753.
12. Steinert H, Huch Böni RA, Böni R, Buck A, Burger C, Berthold T, Burg G, Von Schulthess GK. Metastatic melanoma: staging with whole body FDG-PET and first experience with image fusion of PFT and spiral CT [abstract]. Eur J Nucl Med 1995; 22: 754.
13. Wöhrle H, Feine U, Geiger L, Blessing C, Laniado M, Friese S, Lietzenmayer R, Fierlbeck G, Müller-Schauenburg W. Whole body 18-FDG PET in 46 patients with recurrent malignant melanomas: a comparison versus CT and MR1 [abstract]. Eur J Nucl Med 1995; 22: 753.
14. Everaert H, Flamen P, Franken PR, Bossuyt A. IDAB: a new tracer for scintigraphic visualisation of malignant melanoma [abstract]. Eur J Nucl Med 1995; 22: 753.
15. 99mTc]-sestamibi SPET [abstract]. Eur J Nucl Med 1995; 22: 774.
16. Baum R, Rust M, Strassmann G, Berkefeld J, Wagner R, Hertela A, Caspary W, Höer G. Whole body positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose for preoperative staging of lung cancer: influence on patients' management [abstract]. Eur J Nucl Med 1995; 22: 775.
17. Steinen H, Hauser M, Allemann F, Berthold T, Weder W, Von Schulthess GK. Non-small cell lung cancer: staging by whole body FDG-PET, CT and surgical correlation [abstract]. Eur J Nucl Med 1995; 22: 775.
18. Wunderlich G, Schmidt D, Langen KJ, Ziemons K, Kiwit JCW, Stöcklin G, Müller-Gärtner HW. Evaluation of chemotherapy in gliomas by I-123-α-methyltyrosine SPECT: first results [abstract]. Eur J Nucl Med 1995; 22: 796.
19. De Vadder N, Mortelmans L, Schiepers C, Menten J, Van Loon J, Plets C, De Roo M. Initial clinical experience with F-18 FDG PET in the follow-up of treated primary brain neoplasms [abstract]. Eur J Nucl Med 1995; 22: 796.
20. Müller SP, Jeske J, Geworski L, Kappeler C, Lahmer D, Tamulevicius P, Stolke D, Streffer C, Reiners C, Sciuk J. Comparison of F-18 FDG PET in brain tumor patients with in-vitro analysis of glucose metabolites in biopsies [abstract]. Eur J Nucl Med 1995; 22: 796.
21. 123I-VIP receptor scanning and tag-72 antigen scanning (oncoscint) in patients with gastrointestinal cancer [abstract]. Eur J Nucl Med 1995; 22: 815.
22. Steffens MG, Oosterwijk E, Boerman OC, Oosterhof GON, Koenders E, Debruyne FJM, Corstens FHM. Renal cell carcinoma targeting with I-131 labeled chimeric G250 monoclonal antibody: a phase I study [abstract]. Eur J Nucl Med 1995; 22: 819.
23. Oosterwijk E, Bander N, Divgi C, Welt S, Wakka J, Finn R, Carswell E, Larson S, Warnaar S, Fleuren GJ, Oettgen H, Old L. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 738-750.
24. Buchegger F, Bischof Delaloye A, Gillet M, Doenz F, Achtari C, Vogel CA, Mach JP, Delaloye B. Biokinetics of anti-cea F(ab′)2 simultaneously injected into the hepatic artery and a peripheral vein in patients with liver metastases of colorectal carcinoma [abstract]. Eur J Nucl Med 1995; 22: 822.
25. Shulkin BL, Wieland DM, Shapiro B, Sisson JC. PET studies of pheochromocytomas with C-11 epinephrine [abstract]. Eur J Nucl Med 1995; 22: 836.
26. Béhé M, Mücke HR. New somatostatin analogues labelled with technetium 99-m [abstract]. Eur J Nucl Med 1995; 22: 791.
27. Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Dean RT. Techtide™ Tc-99m-P829: A high-affinity somatostatin receptor-binding peptide exhibiting low GI uptake [abstract]. Eur J Nucl Med 1995; 22: 791.
28. Schomacker K, Wellner U, Gabruk-Szostak B, Gerard H, Steinbach J, Füchtner F, Schicha H. Properties of I-131 therapy capsules affect the radioiodine-biokinetics [abstract]. Eur J Nucl Med 1995; 22: 798.
29. Barrington SF, Kettle AG, Mountford PJ, Thomson WH, Batchelor S, Burrell DN, O'Doherty MJ, Harding LK. Radiation exposure of patients' children at home post I-131 administration [abstract]. Eur J Nucl Med 1995; 22: 798.
30. De Klerk JMH, van het Schip AD, Zonnenberg BA, van Dijk A. Blijham GH, van Rijk PP. Phase I study of Re-186-HEDP in patients with bone metastases originating from breast cancer [abstract]. Eur J Nucl Med 1995; 22: 807.
31. 186Re-HEDP application in bone metastases [abstract]. Eur J Nucl Med 1995; 22: 808.
32. Clunie GPR, Ell PJ. European radiation synovectomy practice 1991-3 [abstract]. Eur J Nucl Med 1995; 22: 829.
33. Behr TM, Sharkey RM, Juweid ME, Aninipot R, Mattes MJ, Stein R, Blumenthal RD, Griffiths GL, Goldenberg DM. Residualizing radiometals (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies [abstract]. Eur J Nucl Med 1995; 22: 765.
34. De Jong M, Breeman WAP, Bernard HF, Rolleman EJ, Hofland LJ, Visser TJ, Setyono-Han B, Bakker WH, van der Pluijm ME, Krenning EP. Evaluation in vitro and in rats of Tb-161-DTPA-Octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy [abstract]. Eur J Nucl Med 1995; 22: 832.
35. Kostakogiu L, Caner B, Uǧur, Sayek I, Ruacan S, Elahi N, Aras T, Bekdik C. Clinical validation of the influence of MDR expression on Tc-99m-sestamibi uptake [abstract]. Eur J Nucl Med 1995; 22: 734.
36. Fantone J, Ward P. Mechanism of inflammation. In: Rubin E, Farber JL, eds. Pathology, 1st edn. Philadelphia: Lippincott, 1988.
37. Van der Laken C, Boerman O, Oyen W, Van de Ven M, Claessens R, Van der Meer J, Corstens F. Comparison of radiolabeled human recombinant interleukin-1 with its receptor antagonist in a model of infection [abstract]. Eur J Nucl Med 1995; 22: 729.
38. Chianelli M, Signore A, Biassoni L, Sobnack R, Procaccini E, Ronga G, Plowman PN, Grossman A, Britton KE, Mather SJ. In vivo imaging of autoimmunity by 99m-Tc-interleukin-2 [abstract]. Eur J Nucl Med 1995; 22: 780.
39. 123I-IL2 for in vivo detection of activated lymphocytes: a scintigraphic and histological study in coeliac patients [abstract]. Eur J Nucl Med 1995; 22: 794.
40. 123I-labelled interleukin-2 in Crohn's disease: assessment of activity state and therapy follow-up [abstract]. Eur J Nucl Med 1995; 22: 795.
41. Becker W, Repp R, Hansen HJ, Goldenberg DM, Wolf F. Binding characteristics and kinetics of a new Tc-99m-antigranulocyte FAB′-fragment (Leukoscan™) [abstract]. Eur J Nucl Med 1995; 22: 728.
42. Harwood SJ, Hakki S, Camblin JG, Morrissey M, Laven DL, Webster WB, Carroll RG. Tc-99m IMMU-MN3 (Leukoscan™) In-111 WBC, and Tc-99m MDP bone scans: diagnostic accuracy in orthopedic infections [abstract]. Eur J Nucl Med 1995; 22: 736.
43. 111In-biotin system [abstract]. Eur J Nucl Med 1995; 22: 736.
44. Vinjamuri S, Hall AV, Solanki KK, O'Shaughnessy EM, Bomanji JB, Siraj Q, Das SS, Britton KE. Tc-99m infection, Tc-I, a bacterial specific infection imaging agent [abstract]. Eur J Nucl Med 1995; 22: 916.
45. Bakker-Woudenberg I, Lokerse A, Ten Kate M, Mouton J, Woodle M, Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1993; 168: 164-171.
46. Boerman OC, Oyen WJG, Storm G, Koenders EB, van Bloois L, Crommelin DJA, van der Meer JWM, Ciaessens RAMJ, Corstens FHM. Imaging experimental focal infection with In111 and Tc-99m-labeled stealth lipsomes [abstract]. Eur J Nucl Med 1995; 22: 728.
47. 123I]-β-CIT and SPET in the diagnosis of movement disorders [abstract]. Eur J Nucl Med 1995; 22: 812.
48. Halldin C, Farde L, Lundkvist C, Nakashima Y, Ginovart N, Karlsson P, Swahn CG, Neumeyer JL, Milius RA, Wang S. Quantitation of dopamine transporters in vivo by PET using a new radioligand. [C-11]β-CIT-FP [abstract]. Eur J Nucl Med 1995; 22: 833.
49. Bergström K, Halldin C, Kuikka J, Lundkvist C, Åkerman K, Swahn C, Hiltunen J, Länsimies E, Neumeyer J, Farde L. Importance of metabolite studies of 1-123 and C-11 labelled β-CIT and analogues with respect to the quantitation of dopamine transporter [abstract]. Eur J Nucl Med 1995; 22: 824.
50. Vermeulen RJ, Booij J, Tissingh G, Janssen AGM, Speelman JD, Wolters EC, van Royen EC. Visualization of dopamine reuptake sites with [123-I]β-CIT SPET in Parkinson's disease and multiple system atrophy [abstract]. Eur J Nucl Med 1995; 22: 812.
51. Brücke T, Asenbaum S, Pirker W, Pozzera A, Wenger S, Wöber C, Müller C, Angelberg P, Podreka I. Quantification of the dopaminergic nerve cell loss in Parkinson's disease with [I-123|-ß-CIT and SPECT [abstract]. Eur J Nucl Med 1995; 22: 812.
52. Kuikka J, Tilhonen J, Bergström K, Hakola P, Karhu J, Ryynanen O, Fohr J, Lansimies E. Altered striatal dopamine transporter density in habitually violent and non-violent alcoholics [abstract]. Eur J Nucl Med 1995; 22: 823.
53. Loch C, Halldin C, Hall H, Bourguignon M, Syrota A, Mazière M, Farde L, Mazière B. In vivo and in vitro visualization of dopamine D2 extrastriatal binding of I-123 epidepride in the human brain [abstract]. Eur J Nucl Med 1995; 22: 824.
54. 123I]-epidepride [abstract]. Eur J Nucl Med 1995; 22: 833.
55. 1A receptors in human brain using [C-11]way-100635 and PET [abstract]. Eur J Nucl Med 1995; 22: 833.
56. Vanhove C, Demonceau G, De Vuyst J, De Rick G, Coleart H, Monte C. A 120 patient normal database for brain SPECT [abstract]. Eur J Nucl Med 1995; 22: 842.
57. Panoutsopoulos G, Petrou A, Skiadas M, Batsakis C, Papanagnou G, Bobolakis K, Savari E, Christacopoulou I. Combined intravenous dipyridamole and bicycle exercise test for thallium SPECT imaging: safety and clinical value [abstract]. Eur J Nucl Med 1995; 22: 744.
58. Faraggi M, Dahan M, Sarda L, Lebtahi R, Legallicier B, Himbert D, François D, Mignon F, Le Guludec D. Asymptomatic patients with chronic dialysis therapy: accuracy of stress thallium-SPECT for the diagnosis of coronary artery diseaese [abstract]. Eur J Nucl Med 1995; 22: 734.
59. 99mTc sestamibi SPET to predict normal results [abstract]. Eur J Nucl Med 1995; 22: 757.
60. Schultz G, vom Dahl J, Banneitz L, Kleinhans E, Buell U. Depth of a myocardial perfusion defect parallels β-oxidation but not glucose metabolism [abstract]. Eur J Nucl Med 1995; 22: 776.
61. Carrió L, Estorch M, López-Pousa J, Bernd L, Torres G. Influence of age and gender on myocardial 123I-MIBG uptake [abstract]. Eur J Nucl Med 1995; 22: 804.
62. Rodriques M, Karanikas G, Rogatti W, Peskar B, Sinzinger H. Radiolabeled lipoprotein(a) in an experimental model of atherogenesis and preliminary studies in humans [abstract]. Eur J Nucl Med 1995; 22: 817.
63. Theissen P, Emmel M, Dietlein M, Scheidhauer K, Schickendantz S, Menniken U, Schicha H. Perfusion scintigraphy of the lungs in children with congenital cardio-pulmonary disease [abstract]. Eur J Nucl Med 1995; 22: 751.
64. Oyen WJG, van Oort AM, Tanke RB, van Mill GJ, Aengevaeren WRM, Corstens FHM. Quantitative assessment of pulmonary perfusion after endovascular stenting of pulmonary artery branch stenosis in corrected tetralogy of Fallot [abstract]. Eur J Nucl Med 1995; 22: 751.
65. Virgolini I, Kurtaran A, Leimer M, Agis H, Angelberger P, Kletter K, Valent P, Linkesch W, Eichler HG. 1231-interferon gamma 1b (IFNγy): inhalation scintigraphy in healthy volunteers [abstract]. Eur J Nucl Med 1995; 22: 732.
66. Stegen M, Wanet P, Metello L., Rubinstein M. Improving sensitivity of thyroid scintigraphy using pinhole SPECT [abstract]. Eur J Nucl Med 1995; 22: 745.
67. Wanet P, Sand A, Abramovici J. High resolution thyroid pinhole SPECT: clinical evaluation after one year experience [abstract]. Eur J Nucl Med 1995; 22: 745.
68. Maurea S, Klain M, Lastoria S, Grivet Fojaja MR, Varrella P, Acampa W, Colao A, Lombardi G, Salvature M. Double-phase technetium-99m MIBI imaging in the evaluation of patients with thyroid adenomas [abstract]. Eur J Nucl Med 1995; 22: 746.
69. Bohuslavizki K, Kerscher A, Fleiner B, Brenner W, Sippel C, Wolf H, Tinnemeyer S, Schramm M, Clausen M, Hense E. Impact of bone scanning on preoperative decision-making in hemimandibular elongation [abstract]. Eur J Nucl Med 1995; 22: 760.
70. Becker W, Döninghaus K, Munzer B, Wildt L, Wolf F. Hysterosalpingoscintigraphy shows functional fallopian tube patency independent from the analomincal situation [abstract]. Eur J Nucl Med 1995; 22: 790.
71. Chen E, MacIntyre W, Go R, Brunken R, Khandekar S. Differences in imaging characteristics of PET and 511 keV SPECT: implications in FDG myocardial viability studies [abstract]. Ear J Nucl Med 1995; 22: 809.
72. Schaefer A, Reiche W, Kirsch CM, Piepgras U. Single photon emission computed tomography of brain tumours using 18 fluorodeoxyglucose: methodical aspects and first results [abstract]. Eur J Nucl Med 1995; 22: 809.
73. Wagner HN. A new era of certainty. J Nucl Med 1995; 36: 13N-28N.
74. Paans A, Nickles R, De Graaf E, Vaalburg W, Reiffers S, Steenhoek A, Woldring M. A dual head anger camera system for the imaging of positron-emitting radionuclides. Int. J Nucl Med Biol 1978;5:266-271.
75. Paans A, Vaalburg W, Woldring M. A rotating double-headed positron camera. J Nucl Med 1985; 26: 1466-1471.